Truffle Capital, an independent venture capital firm focussed on creating and financing start-ups with disruptive technologies in life sciences and information technology, has announced the appointment of Denis Gestin as Chairman of the Board of Directors of Holistick, the first startup company funded by Truffle Capital’s new BioMedTech Crossover fund.
“We’re extremely pleased to welcome Denis Gestin as Chairman of the Board of Holistick. His extensive management experience and track record in successfully launching global medical technologies, including in cardiology, will go a long way for the development of the company and its future commercial success,” says Philippe Pouletty, MD, co-founder and CEO of Truffle Capital and his Truffle partners Antoine Pau, Alain Chevallier, and Vincent Gardès.
Gestin, whose expertise in the field is recognised worldwide, has over 30 years of experience in the management and commercial development of medical technologies companies. Prior to joining Holistick’s Board of Directors, he had been serving as Senior Vice President of Global Commercial Integration at Abbott Laboratories, since January 2017.
Previously, Gestin worked for more than 20 years at St Jude Medical, where he held various executive positions in Europe, the Middle East, Africa, Canada and, more recently, as President of the International Division (OUS), up until 2017. Gestin began his career with Ela Medical Inc (Livanova), where he worked in marketing and business development from 1988 to 1997. A graduate of EDC Paris Business School, Gestin is also a member of the Board of Directors of the Swedish company Acarix.
